Skip to content
OpenCapital
Get started

BridgeBio Pharma BBIO Research and Development Services — Deferred revenue, current portion

Similar metrics at other companies

Alkermes logo
ALKSResearch And Development — Contract With Customer Liability Revenue Recognized
$900K—
Alkermes logo
ALKSResearch And Development — Revenue Remaining Performance Obligation
$1.7M—
Cytokinetics logo
CYTKResearch And Development — Accounts Receivable Net Current
$1.7M-48.5%
Ionis Pharmaceuticals logo
IONSResearch And Development Services — Revenue From Contract With Customer Transaction Price
$582M—
Ionis Pharmaceuticals logo
IONSResearch And Development Services — Payments Included In Transaction Price For Performance Obligation
$582M—
Cytokinetics logo
CYTKResearch And Development Milestone Grant And Other Revenues Net — Accounts Receivable Net Current
$0-100%

Other financials

Income statement

See full
Revenue$194.5M+66.8%
Gross profit$184.6M+61.9%
Operating income-$106.0M-1.5%
Net income-$166.6M+1.8%
EPS (diluted)-$0.84+4.5%

Balance sheet

See full
Cash & equivalents$882.0M+62.5%
Total debt$3.3B+32,101%
Total equity-$2.3B-38.2%
Total assets$1.4B+55.5%

Cash flow

See full
Operating cash flow-$197.3M+1.0%
CapEx$69.0K—
Free cash flow-$197.3M+0.9%

Valuation

See full
Market cap$12.98B+119%
Enterprise value$15.36B+178%
P/S22.4×-24.1×

Profitability

See full
Gross margin95.1%-0.2pp
Operating margin-90.5%-41.2pp
Net margin-125.9%-54.5pp
FCF margin-76.8%—

Returns & leverage

See full
Return on equity-216.8%—
Debt / equity2×—
Current ratio1.5×-3.0×

Where this comes from

Reported directly by BridgeBio Pharma in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.

The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about BridgeBio Pharma's research and development services — deferred revenue, current portion.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BridgeBio Pharma's research and development services — deferred revenue, current portion?
BridgeBio Pharma (BBIO) reported research and development services — deferred revenue, current portion of $800K in Q1 2026.
What does research and development services — deferred revenue, current portion mean?
The portion of payments received for R&D services that the company expects to earn and recognize as revenue within the next year.
How do you interpret research and development services — deferred revenue, current portion?
Higher levels indicate a strong pipeline of near-term revenue, whereas a decline may signal a reduction in short-term service delivery or contract renewals.
How does research and development services — deferred revenue, current portion compare across companies?
Standard current liability classification for any firm with multi-year service contracts or subscription-like R&D arrangements.